4. Program Goals

5. Overview

6. Natalizumab

7. Natalizumab: Recent Label Changes

8. Natalizumab: PML

9. Antibody Index

10. Antibody Index: Case Examples

11. Switching From Natalizumab

12. Switching From Natalizumab (cont)

13. Rituximab

14. Switching to an Oral Agent

15. On the Horizon: Anti-CD20 Agents: Ocrelizumab

16. On the Horizon: Anti-CD20 Agents: Ofatumumab

17. Rituximab Open-Label Phase 2 Study

18. Rituximab: Unresolved Issues

19. Alemtuzumab

20. The Monoclonal Pipeline: Daclizumab

22. Other Developments

23. Summary and Key Points

24. Abbreviations

25. References

26. References (cont)

27. References (cont)

28. References (cont)